KNTE - Kinnate Biopharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-111.8M

Cash

184.7M

Avg Qtr Burn

-25.39M

Short % of Float

3.64%

Insider Ownership

0.21%

Institutional Own.

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIN-3248 (pan-FGFR inhibitor) Details Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.